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The endogenous metabolite of estradiol, 2-Methoxyestradiol
(2ME2), is an antimitotic and antiangiogenic cancer drug candidate
that also exhibits disease-modifying activity in animal models of
rheumatoid arthritis (RA). We found that 2ME2 dramatically sup-
presses development of mouse experimental autoimmune enceph-
alomyelitis (EAE), a rodent model of multiple sclerosis (MS). 2ME2
inhibits in vitro lymphocyte activation, cytokine production, and
proliferation in a dose-dependent fashion. 2ME2 treatment of lym-
phocytes specifically reduced the nuclear translocation and tran-
scriptional activity of nuclear factor of activated T-cells (NFAT) c1,
whereas NF-κB and activator protein 1 (AP-1) activation were not
adversely affected.We therefore propose that 2ME2attenuates EAE
through disruption of the NFAT pathway and subsequent lympho-
cyte activation. By extension, our findings provide a molecular ra-
tionale for the use of 2ME2 as a tolerable oral immunomodulatory
agent for the treatment of autoimmune disorders such as MS in
humans.
calcium signaling | autoimmunity
Multiple sclerosis (MS) is among the most common autoim-mune disorders in the northern hemisphere, affecting ∼0.1%
of the population, primarily young adults (1). The pathological
hallmarks ofMS include demyelination, inflammation, scarring, and
axonal destruction, which result in a variety of clinical symptoms
including sensory loss, visual problems,muscleweakness, and speech
problems (2). The most extensively used animal model of MS is
experimental autoimmune encephalomyelitis (EAE), a T-cell–me-
diated autoimmune disease of the CNS in which inflammatory de-
myelination of the CNS induced by CD4+T lymphocytes specific for
CNS autoantigens such as myelin oligodendrocyte glycoprotein
(MOG) occurs (3). EAE shares many histopathologic and immu-
nologic characteristics withMS, and as such is considered a valuable
model of the human disease (4).
The T helper 17 (Th17) subset of CD4+ lymphocytes is thought
to play a critical role in the pathogenesis of many autoimmune
disorders, including EAE (5). Pathogenicity of Th17 cells is a di-
rect result of the inflammatory cytokines they produce, which in-
clude interleukin (IL)-17A (hereafter called IL-17), IL-17F, IL-21,
IL-22, TNF, and GM-CSF (6). IL-17 itself has received the most
attention as the driving cytokine underlying the autoimmunity of
MS. IL-17 levels are elevated in the circulating leukocytes of MS
patients with active disease, and expression of IL-17 correlates
with MS disease severity (7, 8). Recent studies have revealed the
importance of IL-17 in EAE; mice deficient in either IL-17 or IL-
17 receptor (IL-17R) (9–11) or mice in which IL-17 is neutralized
(12), exhibit attenuated disease.
2-Methoxyestradiol (2ME2) is an endogenousmetabolite of 17β-
estradiol (via conversion to hydroxyestradiols by cytochrome p450
(CYP450) and subsequent methylation by catechol-O-methyl-
transferase) that lacks significant estrogen receptor (ER)-binding
ability (13). Orally active and well tolerated, 2ME2 possesses
antiproliferative, antiangiogenic, and anti-inflammatory properties
(14) and has completed phase I and II clinical trials for the treat-
ment of a broad range of tumor types (15). Mechanistically, 2ME2
is known to bind to tubulin at the colchicine-binding site, resulting
in disruption of microtubule (MT) dynamics and depolymerization
of tubulin (16–18). As a result, G2–M arrest and apoptosis are in-
duced in rapidly dividing cells, whereas quiescent cells are spared
(14). 2ME2 has also been reported to exhibit disease-modifying
activity in autoimmune models of rheumatoid arthritis in rodents
(19–21). In these models, 2ME2 inhibited angiogenesis, leukocyte
infiltration, local inflammation, and bone resorption associated
with disease, but the molecular mechanisms underlying these
phenomena remain undefined. In humans, plasma levels of 2ME2
may increase up to 1,000-fold to 90 nM during the last months of
pregnancy (22, 23), which intriguingly appears to correlate tem-
porally with the remission of clinical symptoms reported in some
pregnant MS and RA patients (24, 25).
In this study, we demonstrate that oral administration of
2ME2 inhibits EAE onset and severity in a dose-dependent
fashion. T- and B-cell activation and proliferation in vitro are
inhibited by 2ME2, as is proinflammatory cytokine production,
including IL-17. Furthermore, we propose that these effects are
linked to 2ME2-mediated inhibition of NFAT activation and
transcriptional activity. Our work thus provides a molecular ra-
tionale for the use of 2ME2 as a treatment for MS.
Results
2ME2 Inhibits Development of EAE in Mice. 2ME2 has been reported
to display anti-inflammatory properties in collagen-induced ar-
thritis (CIA), an autoimmune model of RA dependent on T-cell
activation, and at least partly driven by Th17 cells (26). Given the
importance of T-cell activation and the development of enceph-
alitogenic Th17 cells (27) in orchestrating the inflammatory de-
struction of myelin in EAE, we investigated the therapeutic
potential of 2ME2 in this autoimmune disease model.
S.c. immunization with MOG35–55 in complete Freund’s adju-
vant (CFA), together with injection of petussis toxin (PT), resulted
in induction of EAE in all vehicle (water)-treated mice. Disease
kinetics in these mice was consistent [mean onset at day (d)14–15],
and all mice developed severe disease by d30 (Fig. 1A). In strik-
ing contrast, mice dosed orally throughout the course of the
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experiment (d1 through to d30) with 100 mg/kg Panzem NCD (a
NanoCrystal dispersion formulation of 2ME2 that increases bio-
availability) (28) were completely resistant to EAE and developed
no clinical manifestations of EAE by d30 (Fig. 1A). This inhibition
of EAE was dose dependent, with doses of 10, 30, and 100 mg/kg
producing progressively greater reductions in clinical score (Fig.
1B). The dramatic nature of EAE inhibition by Panzem NCD
when given throughout the disease course prompted us to examine
the ability of 2ME2 to inhibit disease development whenmice were
treated after the induction phase of EAE. Mice were thus dosed
with either vehicle or 100 mg/kg Panzem NCD at d12 after MOG
peptide immunization, and disease course was monitored daily.
Only 1/5 PanzemNCD-treatedmice developed verymild, transient
disease, whereas 4/4 vehicle-treated mice developed EAE by d30
(Fig. 1C). 2ME2 can therefore inhibit development of disease even
when the induction and priming phase of EAE has already oc-
curred. Incidence, onset, mortality rate, and statistical significance
for EAE experiments are reported in Table S1.
EAE is a T-cell–dependent disease. To assay for the presence
of MOG-reactive T cells in Panzem NCD-treated mice (dosed
from d1), we isolated CD4+ T cells from spleens of vehicle- or
drug-treated mice at d12 postimmunization with MOG peptide.
Coculture of these CD4+ T cells with irradiated naïve splenic
antigen presenting cells pulsed with MOG peptide revealed a se-
vere defect in antigen-specific CD4+ T-cell proliferation in T cells
from Panzem NCD-treated mice (Fig. 1D), together with a dra-
matic reduction in MOG-dependent IFNγ and TNFα production
(Fig. 1E). These results show that Panzem NCD effectively cur-
tails the early production and expansion of Ag-specific T cells in
this disease model.
Histopathological analyses of brain tissue 30 d after MOG im-
munization revealed dense immune cell infiltrates in the cerebrum
and cerebellum of vehicle-treated mice (Fig. 1F, HE). Immuno-
histochemical staining indicated a perivascularly centered, diffuse,
widespread infiltrate of CD3+ T cells, which was absent in Panzem
NCD-treated animals (Fig. 1F, CD3). The recruitment of bone-
marrow–derived myeloid cells has been shown to be crucial for
development of EAE (29). Accordingly, extensive perivascular
macrophage activation was apparent in vehicle-treated mice,
whereas activated macrophage staining was dramatically reduced
in Panzem-treated mice (Fig. 1F, Mac3). Moreover, whereas ve-
hicle-treated mice showed large numbers of reactive GFAP+
astrocytes within the infiltrated areas (a sign of severe CNS in-
flammation), a pronounced reduction in the number of reactive
astrocytes was detectable in the Panzem NCD-treated group (Fig.
1F, GFAP). Taken together, these results show that 2ME2 inhibits
EAE in a dose-dependent manner by blunting the inflammatory
response in the CNS.
2ME2 Inhibits T- and B-Cell Proliferation and Activation. To in-
vestigate the effects of 2ME2 on T-cell activation directly, we
pretreated purified CD4+ T cells with 2ME2 or vehicle and mea-
sured proliferation by [3H]thymidine incorporation at 24 h or 48 h
post–T-cell receptor (TCR) stimulation. 2ME2 caused a dose-
dependent inhibition of anti-CD3/28 or phorbol myristate acetate
(PMA) and calcium ionophore (iono)-dependent proliferation
(Fig. 2A). 2ME2 also blocked up-regulation of the early T-cell ac-
tivationmarkers CD25 andCD69 in response to TCR ligation (Fig.
2 B and C and Fig. S1A) and pharmacological activation by PMA/
iono (Fig. S1B). The inhibition of T-cell activation and proliferation
at 24 h by 2ME2was not due to induction of cell death because only
a modest 2ME2-dependent increase in apoptosis was observed in
unstimulated 2ME2-treated T cells, whereas none was apparent in
activated 2ME2-treated T cells (Fig. S1C). At 48 h poststimulation,
however, 2ME2-treated activated T cells showed reduced viability,
presumably due to a 2ME2-dependent defect in activation.
2ME2 had a similar inhibitory effect on the proliferation of
purified splenic B cells, regardless of whether they were stimu-
lated with soluble anti-IgM, anti-IgM/CD40, or lipopolysaccha-
ride (LPS) (Fig. S1D). The up-regulation of CD69 observed in
activated B cells was also prevented by 2ME2 (Fig. S1E).
We also examined the effect of 2ME2 on proliferation of
human T cells in vitro. Stimulation of human peripheral blood
lymphocytes with anti-CD3/28 antibodies resulted in robust
proliferation, which was inhibited in a dose-dependent manner
by 2ME2 (Fig. 2D). In summary, we found that 2ME2 inhibits
activation of lymphocytes in a dose-dependent manner.
T-Cell Cytokine Expression Is Attenuated by 2ME2. Analysis of
mRNA transcripts by quantitative real-time (QRT) PCR revealed
Fig. 1. Panzem NCD treatment inhibits EAE. (A) Mice orally dosed with
vehicle or 100 mg/kg/d Panzem NCD (d1 to d30) were immunized s.c. with
MOG peptide in CFA followed by i.p. injection of PT. Disease severity was
scored daily and is representative of two independent experiments. (B) EAE
was induced as above, but Panzem NCD was administered at 10, 30, or 100
mg/kg. For A and B, data are shown as mean ± SEM for five mice per group
and are representative of two experiments. (C) Vehicle or Panzem NCD was
administered orally, starting at d12 after immunization. Data shown are
mean clinical scores ± SEM (n = 4–5). (D) CD4+ T cells were isolated from d12
spleens from mice treated as in A with vehicle or Panzem NCD and co-cul-
tured with irradiated naïve splenic antigen presenting cells pulsed with MOG
peptide. T-cell–specific proliferation was assessed by [3H]thymidine in-
corporation. (E) IFNγ and TNFα production from CD4+T-cell cultures stimu-
lated with MOG peptide, assessed by ELISA. Data shown are mean ± SEM for
three mice per group. (F) Representative histopathological analyses of CNS
cross-sections from mice at 30 d post-MOG injection. Brain sections were
stained with H&E (HE) or immunostained to detect CD3 (T cells), GFAP (re-
active astrocytes), or Mac3 (activated macrophages). (Scale bar, 100 μm.)
Arrow, hippocampus; arrowhead, lymphocytic infiltrates; asterisk, sub-
arachnoid space. Data shown are from one mouse per group and are rep-
resentative of three mice pergroup in two independent experiments.
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that 2ME2 decreased the induction of a range of cytokine and
cell surface receptor mRNAs in activated T cells, including IL-2,
TNFα, IFNγ, CD25, and CD44 (Fig. 3A). mRNA levels of the
transcription factor GATA-binding protein 3, which is up-regu-
lated via signal transducer and activator of transcription 6
(STAT6) activation (30), displayed normal induction 3 h post-
stimulation. 2ME2’s effects on IL-17 transcription were particu-
larly dramatic, blocking up-regulation of IL-17 mRNA both after
3 h anti-CD3/28 stimulation (Fig. 3A) and 24 h (Fig. 3B,Left). IL-17
production on restimulation after 5 d activation was also blocked
by 2ME2 (Fig. 3B, Right).
To address the effect of 2ME2 on Th17 cell function, naïve
CD4+ T cells were polarized into Th17 cells, pretreated with
vehicle or 2ME2, and subsequently restimulated with PMA/iono
for 6 h. Whereas 23.2% of Th17-polarized cells treated with ve-
hicle stained positive for IL-17, only 7.3% of Th17-polarized cells
pretreated with 2ME2 were IL-17 positive (Fig. 3C). Production
of IFNγ in these Th17-polarized cells was not dramatically af-
fected by 2ME2 treatment (9.1% vs. 7.3%, vehicle vs. control).
To assess whether 2ME2 modulated T-cell cytokine production
in vivo, we pretreated mice with vehicle or 2ME2 for 2 d and
subsequently injected them with 20 μg Staphylococcus enterotoxin
B (SEB), which induces TCR-dependent proinflammatory cyto-
kine production (31). 2ME2-treated mice produced significantly
less serum TNFα and IL-6 than controls (Fig. 3D). These results
show that 2ME2 reduces the production of inflammatory cyto-
kines in vitro and in vivo.
2ME2 Inhibits NFAT Activation, but Has No Effect on NF-κB or AP-1
Signaling. Estrogens are known to confer protection against MS
and EAE (25). Recent work has implicated the G-protein–coupled
estrogen receptor (GPER, also known as GPR30) 1 as a mediator
of the protective role of 17-β estradiol in EAE (32–34). Whereas
2ME2 exhibits poor affinity for the ER, exhibiting 500- and 3,200-
fold lower affinity than estradiol for ERα and ERβ, respectively
(13), its affinity for GPER1 has not been reported. Accordingly,
we determined the role of GPER1 signaling in attenuation of T-
cell activation by 2ME2, using CD25 and CD69 expression 6 h
postactivation as an indicator of inhibitory activity. To this end,
we preincubated purified T cells with 2ME2 and G15, a specific
Fig. 2. Proliferation and activation of T cells is inhibited by 2ME2. (A) CD4+
T cells were pretreated with the indicated concentrations of 2ME2 and left
untreated (circles), stimulated with plate-bound anti-CD3/28 (triangles), or
PMA/iono (squares). Proliferation was assayed 24 h (Left) or 48 h (Right) later
by [3H]thymidine incorporation. (B) T cells were left unstimulated (gray
histograms) or stimulated with anti-CD3/28 in the presence of 0–50 μM
2ME2. CD25 expression on CD4+ (red histograms) and CD8+ cells (green
histograms) was assessed at 6 or 24 h poststimulation by flow cytometry. (C)
Quantification of CD25 expression in CD4+ T cells left untreated (gray bars)
or pretreated with increasing concentrations of 2ME2 and stimulated with
anti CD3/28 for 6 or 24 h (black bars. (D) Human PBMCs were activated with
antihuman CD3/28 in the presence of increasing concentrations of 2ME2.
Proliferation was determined 24 or 48 h later by [3H]thymidine incorporation.
Data are mean ± SD of triplicate determinations and are representative of
three separate donors. For A and D, data shown are the mean ± SD of trip-
licate determinations and are representative of three experiments. For B and
C data are representative of three experiments.
Fig. 3. 2ME2 treatment impairs cytokine production by activated T cells. (A)
T cells were pretreated with vehicle or 2ME2 (50 μM) and stimulated with
anti-CD3/28 for the indicated times. Relative expression levels of the indicated
mRNAs were determined by real-time PCR. (B) T cells were pretreated with
the indicated doses of 2ME2 and left unstimulated (−) or stimulated (+) with
anti-CD3/28 for 24 h (Left) or stimulated for 5 d, preincubated with 2ME2, and
restimulated for 4 h (Right). Induction of IL-17 mRNA was evaluated by QRT-
PCR. For A and B, data are shown as mean fold increase ± SD of triplicate
determinations and are representative of two independent experiments. (C)
Naïve CD4+ T cells were differentiated into Th17 cells, preincubated with
vehicle or 2ME2 for 30 min, and stimulated for 6 h with PMA/iono. IL-17
production in these cells was assessed by flow cytometry. Histograms show
IL-17 staining in the absence (gray) and presence (black) of 50 μM 2ME2,
whereas data values indicate percentage of IL-17 positive cells. Data are
representative of two independent experiments. (D) Mice were dosed with
vehicle (black bars) or 100 mg/kg 2ME2 (clear bars) for 2 d and injected with
25 μg SEB. Serum was collected at the indicated times post-SEB and levels of
the indicated cytokines were analyzed by CBA. Data shown are the mean ±
SD of three mice per group, each individual result being derived from trip-
licate determinations. *P < 0.05, **P < 0.01, ***P < 0.001.
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GPER1 antagonist, subsequently activating the cells with anti-
CD3/28. Blockade of GPER1 with G15 failed to reverse the in-
hibitory effect of 2ME2 on CD25 or CD69 expression (Fig. S2 A
and B), indicating that 2ME2 does not exert its modulatory effects
on T cells through GPER1 activation. When we tested the effect
of G1, a specific agonist of GPER1, on CD25 and CD69 expres-
sion on activated T cells, we found that G1 had no effect on either
parameter (Fig. S2C), supporting the fact that the mechanism of
action of 2ME2 in T cells does not involve GPER1 signaling.
TCR ligation activates the transcription factor NF-κB, the
MAPK pathway that triggers the AP-1 transcriptional complex,
and the activation of NFAT (35). NFAT acts in concert with NF-
κB and AP-1 to modulate the expression of genes critical for
cellular activation and proliferation. To determine the effect of
2ME2 on these signaling pathways downstream of the TCR, we
pretreated T cells with vehicle or 2ME2 and stimulated them with
PMA/iono. IκBα phosphorylation and degradation were normal
in 2ME2-treated activated T cells (Fig. 4A), as was the binding of
NF-κB to DNA as assessed by EMSA (Fig. 4B). 2ME2 did not
inhibit ERK or protein kinase B (AKT) phosphorylation, whereas
the modest hyperphosphorylation of JNK 1 and 2 present even in
the absence of stimulation (Fig. 4A) presumably reflects the
known activation of the stress kinase pathway by 2ME2 (36, 37).
These data are consistent with the observation that 2ME2 in-
duced a modest increase in AP-1 binding to DNA (Fig. 4B). In
addition, 2ME2 did not inhibit NF-κB p65, JNK, or ERK phos-
phorylation in T cells activated with anti-CD3/28 (Fig. S3). Thus,
2ME2 has no apparent inhibitory effect on the signaling media-
tors NF-κB, AP-1, ERK, AKT, or JNK.
Pretreatment with 2ME2 did however reduce the amount of
NFATc1 present in the nuclear fraction of T cells at 30–60 min
after PMA/iono stimulation (Fig. 4C,Left), as well as in T cells and
B cells 24 h after anti-CD3/28 stimulation and anti-IgM/CD40-
stimulation, respectively (Fig. 4C, Right). To confirm that 2ME2
caused a specific defect in NFAT activation, we used Jurkat cell
lines stably transfected with NF-κB and NFAT luciferase report-
ers. Luciferase secretion was dependent on NF-κB or NFAT
transcriptional activity and was triggered via TCR activation with
anti-CD3/28 antibodies (Fig. 4D). Addition of 2ME2 to these
cultures before stimulation revealed that 2ME2 had no effect
on NF-κB–dependent transcriptional activity; however, transcrip-
tional activation of NFAT via TCR ligation was dramatically
inhibited by 2ME2 in a dose-dependent fashion (Fig. 4D). To-
gether, our findings strongly suggest that 2ME2 blocks lymphocyte
activation and proliferation by inhibiting NFATc1 nuclear trans-
location and NFAT-dependent gene transcription.
Discussion
The observation that exogenous 2ME2 induces cell cycle arrest
and apoptosis in a variety of rapidly dividing cells (14, 17, 38) has
led to the proposal that endogenous 2ME2 is a major mediator of
the antimitogenic properties of estradiol (39). In addition to its
antiproliferative and antimitogenic effects, 2ME2 also appears to
possess anti-inflammatory activity in mice (20, 40), although the
mechanism of action remains unclear.
The reported activity of 2ME2 in rodent CIA models led us to
investigate the efficacy of 2ME2 in EAE, which shares many key
disease drivers with CIA, including Th17 cell development and
pathogenic cytokine production. Interestingly, both RA and MS
often enter remission during pregnancy, when serum and urine
2ME2 levels become highly elevated. The enzymes that convert
estradiol to 2ME2 are ubiquitously expressed, and thus any tissue
that is exposed to estradiol can produce 2ME2. It is therefore
tempting to speculate that a rise in 2ME2 concentration in im-
mune organs and/or the CNS may occur during pregnancy, and
allow 2ME2 to reach concentrations necessary to produce disease
modifying effects.
Whereas absorption of 2ME2 is reportedly efficient in mice and
humans, low bioavailability is observed (1.5%) (41), largely at-
tributable to poor solubility and high first-pass metabolic trans-
formation. Although it is difficult to achieve high serum 2ME2
concentrations following oral 2ME2 administration (42), the
precise nature of local 2ME2 tissue accumulation andmetabolism
remains unclear, and it is possible that 2ME2 concentrations in
local areas are significantly higher than those observed in serum.
One approach to address the low solubility of 2ME2 has been the
development of a NanoCrystal dispersion formulation of 2ME2
(Panzem NCD), which increases bioavailabililty to 3–4% (43).
Clinical trials using 2ME2 have routinely used doses of 1 g/d of
2ME2, which result in a steady state Cmax of ∼30–50 ng/mL (27,
43, 44). These doses appear to be largely benign, with few serious
adverse events being recorded. Using allometric scaling (45), a 1-g
dose of 2ME2 in humans can be estimated to be approximately
equivalent to a 200-mg/kg dose in mice. Translation to humans of
the therapeutically effective dose administered to mice in this
study, 100mg/kg orally administered PanzemNCD,would thereby
require half of what has been routinely administered to humans
Fig. 4. 2ME2 disrupts NFAT signaling while leaving NFκB signaling intact. (A)
Purified T cells pretreated with 2ME2 (50 μM) were stimulated with PMA/iono
for the indicated times. Whole cell lysates were subjected to immunoblotting
to detect the indicated proteins. (B) Nuclear lysates were analyzed by EMSA
to detect DNA binding to NF-κB or AP-1. FP, free probe. (C) Purified T cells or
B cells were pretreated with vehicle (−) or 50 μM 2ME2 (+) and were stimu-
lated with PMA/iono for 30 or 60 min (Left) or with anti-CD3/28 or anti-IgM/
CD40 for 24 h (Right). Nuclear fractions of lymphocytes were analyzed by
immunoblotting to detect nuclear translocation of NFATc1. Lamin A, nuclear
protein loading control; NS, nonspecific band. For A–C, data are representa-
tive of at least two independent experiments. (D) Stably transfected NF-κB
and NFAT Jurkat luciferase reporter cell lines were preincubated with 2ME2
for 30 min and stimulated via cross-linking of anti-CD3/28 antibodies with
goat antimouse antibodies (GaM). Five hours later, secreted luciferase activity
indicates relative transcriptional activity. Data are reported as normalized
luciferase activity and are representative of three independent experiments.
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in prior trials with this agent. Disease development after T-cell
priming was also disrupted, suggesting that 2ME2 suppresses T-cell
effector function. These results may imply a potential therapeutic
use of Panzem NCD in human MS.
To elucidate the mechanism of action underlying this activity
in EAE, we determined whether 2ME2 affected signaling events
immediately following antigen receptor TCR ligation in T cells.
CD25 up-regulation and production of IL-2 are both pre-
requisites for efficient T-cell expansion in response to TCR
stimulation (35, 46) and are (together with CD69 expression)
dependent on NFAT nuclear translocation and subsequent
NFAT transcriptional activity (47–49). Whereas NF-κB and
MAPK pathways were unaffected by 2ME2 treatment, NFAT
nuclear localization and transcriptional activity, together with
CD25 and CD69 expression, were dose-dependently inhibited by
2ME2. In addition, we have shown that up-regulation of mRNAs
for the NFAT-dependent genes IL-2, IFNγ, IL-4, TNFα, CD25,
and IL-17 (50) that occurs in response to TCR ligation was
inhibited by 2ME2 treatment. The ability of 2ME2 to inhibit IL-
17 production in Th17-polarized cells may be particularly rele-
vant to its disease-modifying role in EAE, IL-17 being a crucial
encephalitogenic cytokine in the pathogenesis of EAE (6).
Our hypothesis that 2ME2 exerts its effects by impairing
NFAT function in T cells was supported by in vivo experiments.
In mice, SEB treatment induces TNFα production by T cells,
leading to experimental toxic shock (31). We show that pre-
treatment of mice with 2ME2 significantly reduced the amount
of TNFα and IL-6 produced by mice in response to SEB in-
jection. In contrast, 2ME2-pretreated mice that were injected
with LPS, which causes experimental septic shock, showed no
reduction in serum TNFα levels (Fig. S4). SEB-induced TNFα
production by T cells depends on NFATc2 (another calcium-
dependent NFAT family member), whereas LPS-induced TNFα
production is attributable largely to macrophages and depends
on TLR4 signaling, and is not Ca2+ dependent. Our results are
thus consistent with a previous report showing that NFATc2-
deficient mice are not susceptible to toxic shock, but retain
sensitivity to LPS injection (51). Although it has been reported
that 2ME2 interferes with NF-κB transcriptional activity (52),
these studies were performed in DAOY cells, an adherent me-
dulloblastoma cell line, which may account for the differences
observed between our study and that of Kumar et al. (52). Taken
together, these data strongly suggest that disruption of NFAT
activity is largely responsible for 2ME2’s inhibitory effects on
lymphocytes in vitro and on EAE progression in vivo.
In conclusion, our study shows that 2ME2 reduces NFAT
activity specifically. This impairment compromises the activation
and proliferation of lymphocytes and may underlie 2ME2’s dis-
ease-modifying activity in both RA and EAE. Our promising
EAE data in mice, together with favorable preclinical results and
safety data obtained from oncology patients, strongly suggest that
oral 2ME2 may be a well-tolerated, safe, and convenient alter-
native to current biologic and small molecule drugs used in the
treatment of autoimmune disorders such as MS and RA.
Methods
Mice. All live animal experiments were approved by the Institutional Animal
Care and Use Committee (University Health Network, Toronto) as regulated
by the Canadian Council on Animal Care. For all mice experiments C57/BL6
mice were used (Jackson Laboratories).
EAE. Mice were randomly assigned to cages in groups of five, designated as
vehicle or drug treated, and dosed p.o. via a feeding needle with 10–100 mg/
kg 2ME2 (Panzem NCD, Entremed) or vehicle (water) at d1 to d30 or from
d12 to d30. A dose of 100 mg/kg has been reported to be effective for in-
hibition of rodent CIA (20, 21, 53) and as such, was chosen as a starting point
for EAE studies. For EAE induction, mice were s.c. immunized with 115 μg
MOG 35–55 peptide (Washington Biotech) emulsified in CFA (Difco) sup-
plemented with 400 μg/mL Mycobacterium tuberculosis (Difco). On days
0 and 2 postimmunization, mice were i.p. injected with 300 ng pertussis
toxin (List Biological). Clinical signs of EAE were monitored daily according
to the following criteria: 0, no disease; 1, decreased tail tone; 2, hind limb
weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and
hind limb paralysis; and 5, moribund state. Mice were killed when they
reached an EAE disease score of 4, and these animals were assigned a score
of 5 for the rest of the observation period for the purposes of calculating the
mean EAE disease score. At the end of the 30-d observation period, any
surviving mice were killed and their brains subjected to histological analyses.
The study was performed unblinded, but was scored by two independent
researchers who obtained identical results.
Lymphocyte Purification. All lymphocyte subsets were purified to >95% using
the I-Mag magnetic bead separation system (BD Biosciences).
Drug Treatment in Vitro. Cells were preincubated with various concentrations
of 2ME2 (Entremed) or vehicle (DMSO) for 30 min at 37 °C.
Lymphocyte Activation, Proliferation, and Viability. Purified CD4+ T cells were
stimulated with plate-bound anti-CD3 (clone 2C11; BD Biosciences; 10 ng/
mL) plus anti-CD28 (clone 37.51; BD Biosciences; 100 ng/mL). Purified B220+ B
cells were stimulated with anti-IgM (Jackson Laboratories; 5 μg/mL), anti-
CD40 (clone 3/20; BD Biosciences; 5 μg/mL), or LPS (Sigma; 20 μg/mL) for the
times indicated in Fig. 3. CD25 and CD69 expression was determined by flow
cytometry (FACSCanto II; BD Biosciences) and analyzed using FlowJo soft-
ware (Treestar). Proliferation was assessed by [3H]thymidine incorporation.
Viability and up-regulation of cell surface markers on activated T cells
were assessed by flow cytometry using annexin V and propidium iodide.
Human peripheral blood mononuclear cells (PBMCs) were isolated using
Mono-Poly resolving medium (MP Biomedical) according to the manu-
facturer’s protocols and activated with anti-CD3 (clone UCHT1) and anti-CD28
(clone CD28.2).
Quantitative Real-Time PCR. Total mRNA and cDNAs were prepared from
stimulated T cells and cDNAs added to a Low Density TaqMan array (ABI)
according to the manufacturer’s instructions. Fold increase for mRNAs was
determined by normalizing against the expression of GAPDH. For IL-17
mRNA, quantitative RT-PCR was performed using Sybr Green (Invitrogen)
and fold increase was determined by normalizing against 18S rRNA.
SEB and LPS Injections. Mice were dosed i.p. for 2 d with 100 mg/kg 2ME2
(Panzem NCD) or vehicle, then injected i.p. with 25 μg SEB (Sigma) or 500 μg
LPS (055:B5; Sigma). Serum cytokine levels were assessed with the cytometric
bead array (CBA; BD Biosciences) according to manufacturer instructions.
Statistical significance was calculated using Student’s t test.
GPER1 Dependence. Purified C57/BL6 CD4+ T cells were preincubated with the
GPER1 antagonist G15 (100 nM; Tocris) and 2ME2 (0–50 μM) or the GPER1 ag-
onist G1 (1–100 nM; Tocris) for 30min, and activatedwith plate-bound anti-CD3
plus soluble anti-CD28. Six hours later, cells were harvested and stained with
anti-CD4 and anti-CD25. CD25 expressionwasmonitored on a High Throughput
Sampler FACSCanto II (BD Biosciences) and analyzed with FlowJo (Treestar).
Biochemical Dissection of Signaling Pathways.Whole cell lysates of stimulated
T cells were immunoblotted with Ab recognizing phospho-AKT (Ser473),
phospho-JNK (Thr183/Tyr185, p46 and p54 clone G9, antibody “2”), phospho-
ERK (Thr202/Tyr204) or phospho-IκBα (Ser32) (NEB); phospho-JNK (Thr183/
Tyr185, p54 pSAPK/JNK, clone G7, antibody “1”) or IκBα (C21) (Santa Cruz),
β-tubulin (Millipore), or actin (Sigma). Infrared dye-labeled secondary Ab
(antirabbit Alexa Fluor 680; Invitrogen and antimouse IR800; LICOR) were
visualized with the Odyssey scanner (LICOR).
EMSA. Nuclear extracts of T cells stimulated with PMA (10 ng/mL) and calcium
ionophore A23187 (iono; Sigma) (50 ng/mL) for 30 or 60 min were prepared
according to a standard protocol. These extracts were subjected to EMSA
using infrared dye end-labeled DNA oligonucleotides (LICOR) specific for
NF-κB and AP-1 and a protocol specified by the manufacturer. Complexes
were visualized on the Odyssey scanner (LICOR).
NFATc Analysis. T or B cells preincubated with vehicle or 2ME2 (50 μM) were
stimulated with PMA (10 ng/mL) and iono (50 ng/mL), plate-bound anti-CD3
(30 ng/mL) + anti-CD28 (100 ng/mL), or anti-IgM (1 μg/mL) and anti-CD40
(1 μg/mL). Nuclear extracts (5 μg protein) were immunoblotted with anti-
NFATc1 (clone 7A6; Santa Cruz) and anti-lamin A (clone H-102; Santa Cruz).
Gaussia Luciferase Assays. Luciferase assays were performed using Jurkat cells
harboring a stably integrated Gaussia luciferase reporter gene under the
21038 | www.pnas.org/cgi/doi/10.1073/pnas.1215558110 Duncan et al.
control of NF-κB or NFAT binding sites (termed NFAT/NF-κB–GLuc reporter
Jurkat). Gaussia luciferase contains a secretion peptide sequence mediating
quantitative secretion of active enzyme into the surrounding medium. A
total of 1.5 × 105 GLuc reporter cells were stimulated in 96-well plates for
5 h. For each sample, 20 μL of supernatant was subjected to a Gaussia lucif-
erase assay. Luciferase activity was measured in 96-well plates using an Orion
L Microplate Luminometer (Berthold Detection Systems) with an integration
time of 3.0 s. In parallel, cell viability was determined using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega) and normalized GLuc activity was
calculated as the ratio between GLuc activity and cell viability counts.
Statistical Methods. Where appropriate, all differences were evaluated using
the two-tailed Student t test as calculated using Excel (Microsoft) software.
Data are presented as the mean ± SEM, or mean ± SD. For EAE experiments,
the Mann–Whitney test was used.
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